Agilent to Shift Life Science Focus from R&D to Profits | GenomeWeb

CHICAGO (GenomeWeb News) – Agilent Technologies is looking to generate a greater return on its R&D investments in the life science space, according to a company official.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.